Menopause and HRT Discussion

Clinical Scenario

Meena Patel, 49, presents via video consultation to discuss hot flushes. She has been experiencing vasomotor symptoms for 6 months including night sweats disrupting her sleep, hot flushes at work causing embarrassment, low mood, and joint stiffness. Her PMH includes lower back pain and arthritis in her hands. She is currently on naproxen and amitriptyline. She has researched HRT online and is keen to start but is worried about breast cancer risk after reading conflicting information.

What This Case Tests

Making a clinical diagnosis of perimenopause based on age and symptoms without requiring blood tests; conducting a risk-benefit assessment for HRT; addressing media-driven fears about breast cancer risk with accurate evidence; presenting both hormonal and non-hormonal options; shared decision-making around HRT initiation.

Common Mistakes Trainees Make

The three most common mistakes are: ordering unnecessary investigations (FSH testing is not recommended in women over 45 with typical menopausal symptoms — this is a clinical diagnosis), focusing exclusively on HRT without exploring non-hormonal options and lifestyle modifications, and either understating or overstating the breast cancer risk — the absolute risk increase with combined HRT is small but real and should be presented in context.

The Consultation Challenge

Meena has done her research and arrives with a clear request for HRT. This is a well-informed patient with a strong agenda — the consultation tests whether you can match her engagement with evidence-based information while addressing her specific anxieties.

Start by confirming the diagnosis. In a woman aged 49 with hot flushes, night sweats, mood changes, and joint symptoms, the diagnosis of perimenopause is clinical. NICE explicitly states that FSH testing is not required in women over 45 with typical symptoms. A trainee who orders bloods before discussing treatment wastes time and demonstrates poor guideline knowledge.

Take a focused symptom history: vasomotor symptoms (frequency, severity, impact on sleep and work), urogenital symptoms (vaginal dryness, urinary frequency), mood changes, musculoskeletal symptoms, and impact on quality of life. Ask about her menstrual pattern — is it becoming irregular, heavier, or lighter?

The risk-benefit discussion is the core of this case. Meena is worried about breast cancer. Present the evidence clearly using absolute numbers: for combined HRT taken for 5 years from age 50, the additional breast cancer risk is approximately 4 extra cases per 1,000 women. Contextualise this: obesity and regular alcohol consumption each carry a similar or greater additional risk. The benefits of HRT include significant symptom relief, cardiovascular protection when started under 60, bone protection, and potential cognitive benefits.

Explore the medication interactions. Meena takes naproxen for arthritis — consider whether HRT might help her joint symptoms (oestrogen has musculoskeletal benefits). Amitriptyline 10mg at night may be partially managing vasomotor symptoms already — but it is not a recommended treatment for menopause and has significant side effects.

Present the options: body-identical transdermal oestrogen (patches or gel) with micronised progesterone is the preferred first-line per NICE, carrying the lowest thrombotic risk. Discuss the alternative of non-hormonal options (CBT, lifestyle modifications, SSRI/SNRI if HRT contraindicated) for completeness, even though Meena is keen on HRT.

Time check: Spend the first 3 minutes confirming the diagnosis and symptom impact. By minute 6, address the breast cancer concern with clear evidence. Use minutes 7-10 for the HRT discussion including preparation type and route. Reserve the final 2 minutes for prescribing details, monitoring plan, and follow-up.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you make a clinical diagnosis of perimenopause based on age and symptoms without ordering unnecessary investigations (FSH is specifically not recommended per NICE in women over 45). They look for a thorough symptom assessment covering vasomotor, urogenital, psychological, and musculoskeletal domains, a review of current medications and potential interactions, and screening for contraindications to HRT (personal or family history of breast cancer, VTE, cardiovascular disease, liver disease).

Clinical Management and Medical Complexity: Heavily weighted. Examiners expect knowledge of current NICE guidance on HRT: transdermal oestrogen as preferred route (lower VTE risk than oral), micronised progesterone for endometrial protection, body-identical preparations as first-line. They look for accurate risk communication using absolute numbers, awareness of non-hormonal alternatives, and a practical prescribing plan (preparation, dose, monitoring, review at 3 months). Demonstrating awareness of the amitriptyline interaction and the potential musculoskeletal benefits of HRT shows clinical depth.

Relating to Others: Examiners assess whether you engage with Meena's existing knowledge rather than lecturing, whether you address her specific breast cancer anxiety with empathy and evidence, and whether the decision genuinely feels shared. A trainee who either dismisses the risk or exaggerates it will score poorly — calibrated, honest communication is what the examiner values.

Example Opening

Strong opening: "Hello Meena, I can see you'd like to discuss your hot flushes. Before we talk about treatment options, can you tell me how these symptoms have been affecting your daily life? I want to understand the full picture."

When addressing breast cancer risk: "I know the breast cancer question is a big one, so let me give you the actual numbers. For women your age taking combined HRT for 5 years, the additional risk is about 4 extra cases of breast cancer per 1,000 women. To put that in perspective, being overweight or drinking more than 2 units of alcohol daily carries a similar increase. It's a real risk, but a small one — and it has to be weighed against the significant benefits you'd get for your symptoms, your bones, and potentially your heart health."

Avoid: "HRT is very safe these days — you don't need to worry about breast cancer." (Oversimplifies and dismisses a legitimate concern).

How This Appears in the SCA

Menopause management is a high-frequency SCA topic. Examiners assess whether you can make a clinical diagnosis without unnecessary investigation, present the risk-benefit analysis clearly using absolute numbers, demonstrate knowledge of HRT preparations and routes, and engage in genuine shared decision-making with a well-informed patient.

Key Statistic

For combined HRT started in women aged 50-59, the additional breast cancer risk is approximately 4 extra cases per 1,000 women over 5 years. Transdermal oestrogen with micronised progesterone carries the lowest risk profile. HRT initiated before age 60 is associated with cardiovascular protection.

Relevant Guidelines

• NICE NG23: Menopause — diagnosis and management
• British Menopause Society guidelines on HRT prescribing.

Frequently Asked Questions

Do I need to order FSH to diagnose menopause in the SCA?

No. NICE explicitly states that in women over 45 with typical menopausal symptoms, the diagnosis is clinical and FSH testing is not required. Ordering unnecessary blood tests wastes consultation time and demonstrates poor guideline knowledge. FSH is only indicated in women under 45 where premature ovarian insufficiency is suspected, or in women aged 40-45 where the diagnosis is uncertain.

How should I present the breast cancer risk of HRT?

Use absolute numbers, not relative risk. For combined HRT taken for 5 years from age 50, the additional risk is approximately 4 extra breast cancer cases per 1,000 women. Contextualise this against comparable lifestyle risks (obesity, alcohol) and against the benefits (symptom relief, bone protection, cardiovascular benefit when started under 60). The examiner wants to see calibrated risk communication — neither dismissive nor alarmist.

What is the preferred HRT preparation per current NICE guidance?

Body-identical transdermal oestrogen (patches or gel) with micronised progesterone is the preferred first-line combination. Transdermal oestrogen carries the lowest VTE risk compared to oral preparations. Micronised progesterone (e.g., Utrogestan) has a more favourable breast cancer risk profile than older synthetic progestogens. For women who have had a hysterectomy, oestrogen alone is sufficient.

What non-hormonal options should I mention for menopausal symptoms?

CBT has evidence for managing vasomotor symptoms and mood changes. SSRIs/SNRIs (particularly venlafaxine) can reduce hot flushes and may be appropriate if HRT is contraindicated. Lifestyle modifications include regular exercise, weight management, reducing caffeine and alcohol, and layered clothing. Isoflavones (phytoestrogens) have limited evidence. These should be offered as alternatives, not substitutes, for a patient who is keen on HRT.

When is HRT contraindicated?

Absolute contraindications include current or recent breast cancer, undiagnosed vaginal bleeding, untreated endometrial hyperplasia, active VTE or history of recurrent VTE without anticoagulation, active liver disease, and known thrombophilia. Relative contraindications requiring specialist input include strong family history of breast cancer, previous VTE with an identifiable risk factor, and migraine with aura (for transdermal — but oral is contraindicated). Knowledge of these demonstrates strong Clinical Management.